Research limitations and gaps What we know well Strong evidence : GLP-1 peptides for weight loss Growth hormone peptides elevate GH/IGF-1 Some healing peptides (TB-500 in clinical trials) Mechanism of action for most peptides What needs more research Limited human data : BPC-157: Extensive animal studies, limited human trials Many healing peptides: Great anecdotal evidence, need formal studies Long-term safety (5+ years): Limited data for many research peptides Optimal dosing: Often based on extrapolation from animal studies Why research is limited : Expensive to conduct clinical trials ($millions) No patent protection for most peptides (generic amino acid sequences) Pharmaceutical companies focus on patentable drugs Research peptides exist in regulatory gray area What this means : Some peptides have strong evidence (FDA-approved) Others have good preclinical evidence but limited human trials Anecdotal evidence extensive for many compounds Users serve as "citizen scientists" in some cases How to evaluate peptide research Here are some questions to ask Has it been studied in humans
Acrolein can induce hepatotoxicity characterized by periportal (zone 1) necrosis in rodents [30,31]
If the same active substance shown in the figure above is given via another route, such as a tablet given orally (by mouth), the bioavailability is lower than 100% (see figure below, Oral bioavailability)
Even though insulin was the first therapeutic peptide, synthesized in the 1920s, some more recent peptides that are used for anti-aging, wound healing or muscle recovery are still considered to be in their infancy when it comes to research data
Q6: What about non-alcoholic beverages and supplements
